These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23873482)

  • 21. Intranasal delivery of RS-93522, a dihydropyridine-type calcium-channel antagonist.
    Fu RC; Whatley JL; Fleitman JS
    Pharm Res; 1991 Jan; 8(1):134-5. PubMed ID: 2014202
    [No Abstract]   [Full Text] [Related]  

  • 22. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study.
    Fan H; Gilbert R; O'Callaghan F; Li L
    BMJ; 2020 Feb; 368():m331. PubMed ID: 32075790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults.
    Trac MH; McArthur E; Jandoc R; Dixon SN; Nash DM; Hackam DG; Garg AX
    CMAJ; 2016 Apr; 188(7):E120-E129. PubMed ID: 26903359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular Mechanism of Dihydropyridine Ca
    Yamamura A
    Yakugaku Zasshi; 2016; 136(10):1373-1377. PubMed ID: 27725386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe secondary hyperkalemia and arrhythmia from drug interactions between calcium-channel blocker and voriconazole: a case presentation.
    Zhao X; Zhang C; Zhu L; Wu B; Han Y; Heung M; Zuo L
    BMC Nephrol; 2021 May; 22(1):172. PubMed ID: 33971831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
    Katayama S; Kawamori R; Iwamoto Y; Saito I; Kuramoto K;
    Hypertens Res; 2008 Aug; 31(8):1499-508. PubMed ID: 18971523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation.
    Niedrig D; Maechler S; Hoppe L; Corti N; Kovari H; Russmann S
    Eur J Clin Pharmacol; 2016 Jul; 72(7):859-67. PubMed ID: 27023463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.
    Oparil S; Weber M
    Postgrad Med; 2009 Mar; 121(2):25-39. PubMed ID: 19332960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of dihydropyridine calcium antagonists in hypertensive patients with impaired renal function.
    Hansson LH
    J Cardiovasc Pharmacol; 1989; 14 Suppl 10():S36-9; discussion S59-62. PubMed ID: 2483570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study.
    Lins R; Haerden Y; de Vries C
    High Blood Press Cardiovasc Prev; 2017 Mar; 24(1):29-36. PubMed ID: 28058623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lercanidipine-induced chylous ascites: Case report and literature review.
    Basualdo JE; Rosado IA; Morales MI; Fernández-Ros N; Huerta A; Alegre F; Landecho MF; Lucena JF
    J Clin Pharm Ther; 2017 Oct; 42(5):638-641. PubMed ID: 28485829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydropyridine calcium antagonists: beneficial or adverse effects in the setting of myocardial ischaemia/reperfusion?
    Ehring T; Heusch G
    Cardiology; 1997; 88 Suppl 1():3-14; discussion 15-6. PubMed ID: 9118166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macrolide prescription in Dutch children: compliance with guidelines.
    Bandell RAM; Dekkers T; Semmekrot BA; de Wildt SN; Fleuren HWHA; Warlé-van Herwaarden MF; Füssenich P; Gerrits GP; Kramers C
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):675-681. PubMed ID: 30680574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dihydropyridine calcium channel blockers: a rare and reversible cause of hepatotoxicity with cholestasis in a CAPD patient.
    Basile C; Mascia E
    Nephrol Dial Transplant; 1999 Nov; 14(11):2776-7. PubMed ID: 10534534
    [No Abstract]   [Full Text] [Related]  

  • 35. Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring.
    Kubota K; Pearce GL; Inman WH
    Eur J Clin Pharmacol; 1995; 48(1):1-7. PubMed ID: 7621840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between calcium channel blocker class and mortality in dialysis.
    Wetmore JB; Mahnken JD; Phadnis MA; Ellerbeck EF; Shireman TI
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1249-58. PubMed ID: 26371369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker-Induced Lower-Extremity Edema With Loop Diuretics.
    Vouri SM; Jiang X; Manini TM; Solberg LM; Pepine C; Malone DC; Winterstein AG
    JAMA Netw Open; 2019 Dec; 2(12):e1918425. PubMed ID: 31880802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of calcium channel blockers and mortality in haemodialysis patients.
    Tepel M; Giet MV; Park A; Zidek W
    Clin Sci (Lond); 2002 Nov; 103(5):511-5. PubMed ID: 12401125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of periodontal disease in patients using calcium channel blockers - gingival overgrowth, prescribed medications, treatment responses and added treatment costs.
    Fardal Ø; Lygre H
    J Clin Periodontol; 2015 Jul; 42(7):640-6. PubMed ID: 26076712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dihydropyridine calcium channel antagonists in the management of hypertension.
    Epstein BJ; Vogel K; Palmer BF
    Drugs; 2007; 67(9):1309-27. PubMed ID: 17547473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.